ClinicalTrials.gg
CompletedNCT05559554Updated May 16, 2024

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

A Phase 1 interventional study of AK104 (before the change) and AK104 (after the change) in Healthy Male Subjects, sponsored by Akeso. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Akeso · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of AK104 with different manufacturing process.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • AK104
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged 18 to 45;
  2. (BMI) is 19.0\~28.0 kg/m2, and body weight is 50.0\~80.0kg ;
  3. Signing form before the trial and having a full understanding of the trial content, process and possible adverse reactions;
  4. Able to complete the study according to the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of digestive tract, respiratory, cardiovascular, endocrine, urinary, neurological, hematological, metabolic and other systemic diseases;
  2. Those with a history of diseases;
  3. Those with a history of malignant tumor, unless it is a skin squamous cell carcinoma, basal cell carcinoma or cervical cancer in situ that has been successfully resected and has no evidence of ;
  4. Regular drinkers within 6 months prior to screening;
  5. Those who are suspected or confirmed to be allergic or have had severe drug or food allergy reactions in the past, have a clear history of allergies and/or are allergic to the study drug or its components after inquiries;
  6. Those who have used /PD-L1 or/and anti-CTLA-4 drugs in the past;
  7. Those who have been vaccinated with live or attenuated- within 3 months before screening, or who are expected to receive vaccines during the study period;
  8. Those who lost blood, donated blood or received any blood product transfusion of ≥400 ml within 3 months before screening;
  9. Those who received major surgery or hospitalization due to illness within 3 months before screening;
  10. Abnormal laboratory tests with clinical significance at screening;
  11. Positive drug screening result;
  12. Have a childbirth plan within 6 months from the screening period to the trial drug administration, or who are unwilling to take the measures specified in the protocol during the trial period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    AK104 (after the change)

    Drug: AK104 (after the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.

    Drug: AK104 (after the change)

  • Active comparator
    AK104 (before the change)

    Drug: AK104 (before the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.

    Drug: AK104 (before the change)

Interventions

06

What researchers measure

Primary outcomes

  1. Pilot study: Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to day 30

  2. Pivotal study: Area under the plasma concentration-time curve (AUC0-infinity)

    Time frame: From pre-dose to day 29

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC0-t)

    Time frame: From pre-dose to day 29

  2. Maximum plasma concentration (Cmax)

    Time frame: From pre-dose to day 29

  3. Volume of distribution (Vd)

    Time frame: From pre-dose to day 29

  4. Clearance (CL)

    Time frame: From pre-dose to day 29

  5. Ratio of AUC0-t/AUC0-infinity

    Time frame: From pre-dose to day 29

  6. Time to maximum concentration (Tmax)

    Time frame: From pre-dose to day 29

  7. Half-life (t1/2)

    Time frame: From pre-dose to day 29

  8. Anti-drug Antibody (ADA)

    Number and percentage of subjects with detectable ADA

    Time frame: From pre-dose to day 29

07

Study locations

1 site
  • The Third Hospital of Changsha
    Changsha, Hunan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Mar 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Oct 25, 2022
Primary completionActual
Mar 24, 2023
CompletionActual
Apr 6, 2023
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05559554
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 25, 2022
Primary completion
Mar 24, 2023
Completion
Apr 6, 2023
Last update
May 16, 2024

Study contacts

Xin Li, MD
principal investigator · The Third Hospital of Changsha

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion